zondag, augustus 14, 2022
HomeBusiness(IMV) - IMV's Shares Soar As Ovarian Most cancers Candidate Reveals Total...

(IMV) – IMV’s Shares Soar As Ovarian Most cancers Candidate Reveals Total Survival Charge Of 44.9%


IMV's Shares Jump As Ovarian Cancer Candidate Shows Overall Survival Rate Of 44.9%

  • IMV Inc (NASDAQ: IMV) has announced the final topline results of the DeCidE1 Phase 2 trial evaluating maveropepimut-S (MVP-S, formerly known as DPX-Survivac) for advanced, recurrent ovarian cancer.
  • The results showed that treatment was well-tolerated, with an overall survival rate of 44.9% at 23.8 months of follow-up and a median overall survival of 19.9 months. 
  • The Company noted that many subjects in the trial had been heavily pre-treated, and 57.9% were platinum-resistant. 
  • “The translational analyses provide strong evidence that maveropepimut-S successfully elicits the generation of tumor antigen-specific T cells,” Jeremy Graff, Chief Scientific Officer, commented.
  • The details of these translational analyses have been submitted to upcoming scientific meetings for presentation.
  • Price Action: IMV shares are up 30.90% at $2.20 during the premarket session on the last check Tuesday.

RELATED ARTICLES

LAAT EEN REACTIE ACHTER

Vul alstublieft uw commentaar in!
Vul hier uw naam in

Most Popular

Recent Comments